NPC1L1 Gene Polymorphism and the Efficacy and Safety of Hybutimibe

Inclusion criteria

• Patients with high/very high risk of ASCVD were only treated with moderate intensity statins (including atorvastatin 10-20mg, rosuvastatin 5-10mg, fluvastatin 80mg, lovastatin 40mg, pivastatin 1-4mg, pravastatin 40mg, simvastatin 20-40mg, etc.) for at least 8 weeks before enlistment.
• The LDL-C level did not meet the lipid reduction target corresponding to the risk stratification level of ASCVD recommended by the Chinese Lipid Management Guidelines (2023), or the level of LDL-C was still not up to the standard as clinicians expected that patients should continue to use medium-dose statins for lipid-lowering treatment alone, and the cholesterol absorption inhibitor Hybomab should be combined;
• Age 18-75 years old;
• BMI range 22-45 kg/m2;
• Can understand and voluntarily sign informed consent.

Exclusion criteria

• Allergic history of cholesterol absorption inhibitors and statins;
• other types of cholesterol absorption inhibitors have been used;
• Homozygous familial hypercholesterolemia;
• any clinically serious endocrine disease affecting blood lipids or lipid proteins;
• Abnormal liver function with AST or ALT greater than three times the upper limit of normal, or bilirubin >34uM, creatine muscle enzyme greater than five times the upper limit of normal, or evidence of serologically infectious liver disease;
• Thyroid dysfunction;
• History of malignant tumor;
• Patients with coagulation dysfunction;
• Women who are pregnant or planning to become pregnant;
• Taking fenofibrate, gefilozil, probucol, warfarin, glucocorticoids, cyclosporine or another immunosuppressant within 30 days prior to the trial;
• can not adhere to medication or regular follow-up;
• Communication disorders, people with severe aphasia, audio-visual impairment, serious mental illness, and difficulty cooperating with investigators;
• There are other circumstances that the researcher considers inappropriate to participate in this study.